Scarica l'app Stockscreener
1.31
2.24%
-0.03
Dopo l'orario di chiusura:
1.33
0.02
+1.53%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRBU Giù?
Forum
Previsione
Precedente Chiudi:
$1.34
Aprire:
$1.37
Volume 24 ore:
1.65M
Relative Volume:
1.03
Capitalizzazione di mercato:
$121.34M
Reddito:
$34.48M
Utile/perdita netta:
$-102.07M
Rapporto P/E:
-0.8973
EPS:
-1.46
Flusso di cassa netto:
$-104.90M
1 W Prestazione:
-13.82%
1M Prestazione:
-18.63%
6M Prestazione:
-43.04%
1 anno Prestazione:
-78.42%
Intervallo 1D:
$1.30
$1.37
Intervallo di 1 settimana:
$1.30
$1.55
Portata 52W:
$1.30
$8.33
Caribou Biosciences Inc Stock (CRBU) Company Profile
Nome
Caribou Biosciences Inc
Settore
Industria
Telefono
510-982-6030
Indirizzo
2929 7TH STREET, SUITE 105, BERKELEY
Confronta CRBU con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRBU
Caribou Biosciences Inc
|
1.31 | 121.34M | 34.48M | -102.07M | -104.90M | -1.46 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
Caribou Biosciences Inc Stock (CRBU) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-06-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2023-11-08 | Iniziato | Cantor Fitzgerald | Neutral |
| 2023-10-31 | Iniziato | Evercore ISI | Outperform |
| 2023-07-11 | Iniziato | Truist | Buy |
| 2022-02-18 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-12-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-30 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-15 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-17 | Iniziato | BofA Securities | Buy |
| 2021-08-17 | Iniziato | Citigroup | Neutral |
| 2021-08-17 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Caribou Biosciences Inc Borsa (CRBU) Ultime notizie
Caribou Biosciences stock hits 52-week low at $1.32 - Investing.com
Shareholders that lost money on Caribou Biosciences, Inc.(CRBU) - GuruFocus.com
2025-01-29 | Levi & Korsinsky Notifies Shareholders of Caribou Biosciences, Inc.(CRBU) of a Class Action Lawsuit and an Upcoming Deadline | NDAQ:CRBU | Press Release - Stockhouse Publishing
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GlobeNewswire
2025-01-29 | Investors who Lost Money on Caribou Biosciences, Inc. (CRBU) Should Contact Levi & Korsinsky About Pending Class ActionCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
2025-01-28 | Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Caribou Biosciences, Inc. of Class Action Lawsuit and Upcoming DeadlinesCRBU - PR Newswire
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
CRBU INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Caribou Biosciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - GlobeNewswire Inc.
CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Securities Fraud Lawsuit - PR Newswire
Shareholders that lost money on Caribou Biosciences, Inc. - GlobeNewswire
The Gross Law Firm Notifies Shareholders of Caribou Biosciences, Inc.(CRBU) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
FY2025 Earnings Estimate for CRBU Issued By Leerink Partnrs - Defense World
Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Sold by JPMorgan Chase & Co. - Defense World
TOP RANKED ROSEN LAW FIRM Encourages Caribou Biosciences, - GlobeNewswire
TOP RANKED ROSEN LAW FIRM Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Leerink Partnrs Has Negative Outlook of CRBU FY2025 Earnings - MarketBeat
Caribou Biosciences, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - Victoria Advocate
Equities Analysts Offer Predictions for CRBU FY2025 Earnings - Defense World
Caribou Biosciences stock hits 52-week low at $1.49 - MSN
The Gross Law Firm Announces the Filing of a Securities Class Action on Behalf of Caribou Biosciences, Inc.(CRBU) Shareholders - PR Newswire
Caribou Biosciences stock hits 52-week low at $1.49 By Investing.com - Investing.com Canada
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Caribou Biosciences, Inc. Investors to - The Bakersfield Californian
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - GlobeNewswire
Contact Levi & Korsinsky by February 24, 2025 Deadline to Join Class Action Against Caribou Biosciences, Inc. (CRBU) - GlobeNewswire
Investors who lost money on Caribou Biosciences, Inc.(CRBU) - GlobeNewswire
Class Action Filed Against Caribou Biosciences, Inc. (CRBU) Seeking Recovery for InvestorsContact Levi & Korsinsky - GuruFocus.com
Barclays PLC Has $255,000 Stake in Caribou Biosciences, Inc. (NASDAQ:CRBU) - Defense World
ROSEN, A LEADING NATIONAL FIRM, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionCRBU - Markets Insider
2025-01-20 | Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of February 24, 2025 in Caribou Biosciences, Inc. LawsuitCRBU | NDAQ:CRBU | Press Release - Stockhouse Publishing
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Caribou - GlobeNewswire
ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Levi & Korsinsky Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineCRBU - Stockhouse Publishing
Faruqi & Faruqi Reminds Caribou Biosciences Investors of - GlobeNewswire
ROSEN, TOP-RANKED INVESTOR COUNSEL, Encourages Caribou Biosciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Class Action Filed Against Caribou Biosciences, Inc. (CRBU) - GlobeNewswire
CRBU LAWSUIT ALERT: The Gross Law Firm Notifies Caribou Biosciences, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - Finansavisen
CRBU INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In CRBU To Contact Him Directly To Discuss Their Options - PR Newswire
CRBU Stockholders Have Opportunity to Lead Caribou Biosciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - AccessWire
Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your RightsCRBU - Morningstar
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Caribou Biosciences - Markets Insider
Caribou Biosciences, Inc. Shareholders are Encouraged to - GlobeNewswire
Caribou Biosciences, Inc. Securities Fraud Class Action - GlobeNewswire
Caribou Biosciences Advances CAR-T Therapy Trials - TipRanks
Shareholders of Caribou Biosciences, Inc. Should Contact The Gross Law Firm Before February 24, 2025 to Discuss Your RightsCRBU - PR Newswire
CRBU Investors Have Opportunity to Lead Caribou Biosciences, Inc. Class Action Lawsuit – Contact Bronstein, Gewirtz and Grossman, LLC Today! - AccessWire
Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 - The Manila Times
Caribou Biosciences Launches GALLOP Trial for Lupus, Reports Strong Pipeline Progress & $281M Cash Position - StockTitan
Caribou Biosciences initiates CB-010 GALLOP Phase 1 trial in lupus - TipRanks
Caribou Biosciences Inc Azioni (CRBU) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
5.49%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):